Martin Renatus

Novartis Pharma AG, Switzerland

Martin Renatus obtained his Ph.D. degree in 1998 from the Max Planck Institute of Biochemistry in the group of Professor Robert Huber for his studies on the activation mechanism of plasminogen activators. From 1998 to 2002, he joined The Burnham Institute in La Jolla, Calif, USA, as Postdoctoral Researcher and later as a Junior Associated Professor within the apoptosis and cell death research program. His scientific work focused on the mechanistical understanding of the activation and regulation of proteolytic cascades, namely, the caspases. In 2002, he joined Novartis, Expertise Protease Platform, where he is heading a laboratory dealing with protein expression and crystallography. Since then he has been involved in various drug discovery projects targeting proteases in different diseases.

Biography Updated on 1 November 2011

Scholarly Contributions [Data Provided by scopus]